- Icosavax Inc (NASDAQ:ICVX) has announced topline interim results from its ongoing Phase 1/2 trial of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain (RBD).
- In the naïve setting, adjuvant effect on immunogenicity and a dose-response were observed with IVX-411. However, the level of immune response was comparable to or below the Human Convalescent Sera (HCS) control.
- At day 49, responses were up to 154 IU/mL across dosage groups in the live virus neutralization assay (HCS: 281 IU/mL) and up to 592 BAU/mL across groups in the spike IgG assay (HCS: 361 BAU/mL).
- Pre-versus post-boost fold increases of up to 5x (599 IU/mL) for wild-type virus were observed at day 28 post boost.
- For the omicron variant, neutralizing antibody titers were up to 8-fold lower than observed for wild-type virus.
- IVX-411 was generally safe and well-tolerated. Solicited local and systemic adverse events (AEs) were mild or moderate, without dose-limiting reactogenicity.
- Icosavax will share interim data from the lead RSV program, IVX-121, in 2Q 2022,
- It expects to initiate Phase 1 trial of the combination vaccine candidate, IVX-A12 against RSV and human metapneumovirus, in 2H 2022.
- Price Action: ICVX shares are down 16.8% at $10.35 during the premarket session on the last check Friday
Ohio’s Upcoming Cannabis Legalization Lobby Day Attracts Diverse Organizations
The Ohio Cannabis Lobby Day 2021, taking place on October 13 is meant to educate legislators and the general public about the need for medical marijuana patients rights as well as to legalize and regulate legal weed.
